Display options
Cite
Coiffier B. Rituximab in the treatment of diffuse large B-cell lymphomas. Semin Oncol. 2002;29(1):30-35doi: 10.1053/sonc.2002.30153.
Coiffier, B. (2002). Rituximab in the treatment of diffuse large B-cell lymphomas. Seminars in oncology, 29(1), 30-35. https://doi.org/10.1053/sonc.2002.30153
Coiffier, Bertrand. "Rituximab in the treatment of diffuse large B-cell lymphomas." Seminars in oncology vol. 29,1 (2002): 30-35. doi: https://doi.org/10.1053/sonc.2002.30153
Coiffier B. Rituximab in the treatment of diffuse large B-cell lymphomas. Semin Oncol. 2002 Feb;29(1):30-35. doi: 10.1053/sonc.2002.30153. PMID: 28140089.
Copy Download .nbib Format: NLM
Share it on

Semin Oncol. 2002 Feb;29(1):30-35. doi: 10.1053/sonc.2002.30153.

Rituximab in the treatment of diffuse large B-cell lymphomas.

Seminars in oncology

Bertrand Coiffier

Affiliations

  1. Hospices Civils de Lyon and Université Claude Bernard, Lyon, France.

PMID: 28140089 DOI: 10.1053/sonc.2002.30153

Abstract

A review of the use of rituximab (Rituxan; Genentech, Inc, South San Francisco, CA, and IDEC Pharmaceuticals, San Diego, CA) in diffuse large B-cell lymphomas is presented, focusing on the recent presentation of the combination of CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) plus rituximab in elderly patients. This combination increased the response rates, event-free survival, and overall survival of patients older than 60 years in comparison with CHOP alone. The toxic events observed with the combination were not more numerous or severe than those observed with CHOP alone. Rituximab is a chimeric anti-CD20 antibody that increases the treatment options in patients with B-cell lymphomas. Semin Oncol 29 (suppl 2):30-35. Copyright © 2002 by W.B. Saunders Company.

Copyright © 2002 W.B. Saunders Company. All rights reserved.

Publication Types